BMRNBIOMARIN PHARMACEUTICAL INC
Pharmaceutical Preparations
- Revenue
- $3.2B
- 13% YoY
- Operating margin
- 12.7%
- 25% YoY
- EBITDA
- $489M
- 16% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 6.8×
- $3.3B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear237% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear6% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B | 13% |
| Operating income | −$82M | $161M | $186M | $484M | $409M | 15% |
| Net income | −$64M | $142M | $168M | $427M | $349M | 18% |
| Operating cash flow | $305M | $176M | $159M | $573M | $828M | 45% |
| Capex | $96M | $121M | $97M | $85M | $103M | 21% |
| Stock-based comp | $197M | $196M | $207M | $202M | $181M | 10% |
| Buybacks | $0 | $0 | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 3
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $22M | $12M | 68 | 125 |
| FY2024 | — | — | 75 | 93 |
| FY2023 | — | — | 110 | 94 |
| FY2022 | — | — | 118 | 90 |
| FY2021 | — | — | 101 | 100 |